
Chemical and Pharmaceutical Bulletin p. 1964 - 1972 (2000)
Update date:2022-07-29
Topics:
Okada, Yoshio
Tsuda, Yuko
Tada, Mayako
Wanaka, Keiko
Okamoto, Utako
Hijikata-Okunomiya, Akiko
Okamoto, Shosuke
Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-PIC)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and >400 μM, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and >1000 μM, respectively.
View Moretaizhou creating bio-pharm co.,ltd.
Contact:+86- 576- 88827176
Address:715 room ,unit A.junyue Building,Jiaojiang,Taizhou,Zhejiang,China
Contact:86-310-8067016
Address:East Fuhua Road,Tiexi Chemical Industrial Estate,Hebei,China
Contact:+86 512 6287 2180
Address:398 Ruoshui Road, Suzhou Industrial Park, Suzhou, Jiangsu, P. R. China
Dalian Join King Biochemical Tech. Co., Ltd.
Contact:0411 39216206
Address:814 First State Blvd
Fusilin chemical science & technology co., ltd.
Contact:532-80698166/86057573, +86-400-669-7885
Address:School of Material Science & Engineering, Shandong Uinversity of Science & Technology, Huangdao Zone, Qindao, Shandong
Doi:10.1016/j.jorganchem.2014.06.018
(2014)Doi:10.1039/c9cc06638a
(2019)Doi:10.1016/j.bmcl.2007.04.089
(2007)Doi:10.1021/acs.joc.9b03155
(2020)Doi:10.1039/b007626k
(2000)Doi:10.1016/S0040-4020(01)98216-X
(1971)